OPRD Radar
75 subscribers
18 photos
15 files
88 links
Side channel of @epi_pharm
Download Telegram
#llm #retrosynthesis

Looks like even Nvidia is now jumping in retrosynthesis.
ReaSyn is basically retrosynthesis rebranded in LLM-speak: instead of MCTS grinding through disconnections with extracted templates, it uses a “Chain-of-Reaction” reasoning trace so the model can narrate each step. They blend supervised learning, RL fine-tuning, and heavy decoding tricks to steer the model toward plausible chemistry.
Probably not as scalable as classical MCTS, but it could be handy if transformations are well-curated and the building block space is carefully pre-filtered.

📄https://arxiv.org/pdf/2509.16084
⚙️https://shorturl.at/QvQgt (Model weights)
Please open Telegram to view this post
VIEW IN TELEGRAM
👍3
#oprd

Nice BO use case from ETH Zurich & Novo Nordisk: they co-optimize mAb formulations across Tm, kD, and air–water interface stability, finding good excipients combination in ~33 experiments while keeping pH and osmolality in check.
Still some room for refinement, but great to see BO moving beyond the small-molecule domain.

https://pubs.acs.org/doi/10.1021/acs.molpharmaceut.5c00591
👍2
#rnd

Large-scale cheminformatics analysis by Ertl et al. (SAscore author) maps how ring systems used in medicinal chemistry evolved over time, highlighting which heterocycles dominate today’s drug space and which are fading.
The study links shifts in ring popularity to synthetic accessibility and changing design strategies, offering a data-driven view of scaffold trends valuable for modern drug discovery.

https://chemrxiv.org/engage/chemrxiv/article-details/6891a60123be8e43d6d10ab0
2👍2
#cmc

ICH is merging all stability guides into one big chunk - Q1A–E/Q5C will now live together as just Q1.
What’s new:
– Enhanced emphasis on knowledge- and risk-based approaches
– New or expanded types of stability / supportive studies (f… finally)
– Lifecycle / post-approval changes & commitments
– New Annex for ATMPs and other new modalities

A must-read for the grown-ups in pharma development - you’ll want to be ready for those GAP assessments.🥲

https://www.ema.europa.eu/en/ich-q1-guideline-stability-testing-drug-substances-drug-products
👍1
#oprd

Cheeky robots are now coming for lab coats too, not just IT jobs.
An interesting preprint introduces RAISE - a self-driving lab that fully automates formulation, contact-angle measurement, and optimization in a Bayesian closed loop. It turns surface science from tedious manual work into rapid, data-driven formulation discovery. Not pharma per se, but it could easily be applied there.

https://arxiv.org/abs/2510.06546
👍1
#rnd

Not exactly groundbreaking, but a smart and pragmatic shift from Iktos.
Instead of asking “how do we make this designed molecule?” the authors flip the question to “what can we actually make from what’s already on the shelf - and what can we feed to the robots without endless reconfiguration?
Their cluster synthesis strategy groups diverse reactions into a few shared condition clusters, streamlining execution and cutting setup pain. It’s less about grand design and more about making the most of what’s physically doable - a mindset that feels very relevant for real-world drug discovery labs.

https://chemrxiv.org/engage/chemrxiv/article-details/68de33daf2aff167708137a8 (preprint)
👍1
#rnd

AI for Scientific Discovery is a Social Problem
A tool is only as good as its user.

https://arxiv.org/abs/2509.06580
👍2
#rnd #cmc

This review summarizes key challenges and considerations in translating machine learning models into decision-making tools for real-world drug discovery projects, in particular, related to compound toxicity and safety. This includes making choices about data, modeling, validation, model metrics, and applying the model thus obtained to the process of drug discovery.

https://pubs.acs.org/doi/10.1021/acs.chemrestox.5c00033
👍2
#rnd

The preprint from Bayer applies WISP (Workflow for Interpretability Scoring using matched molecular Pairs) to real chemical datasets like LCAP yields, Factor Xa inhibition, and AMES mutagenicity. It shows how explainability methods can highlight which structural changes (e.g. adding a methyl group) influence model predictions. Importantly, WISP can also reveal when these explanations don’t reflect real chemistry, helping to spot weak or misleading models.

Think of it as a structured way to peek inside the black box and check whether the model is actually learning chemistry or just patterns in the data.

https://chemrxiv.org/engage/chemrxiv/article-details/68bb381ea94eede154ed44f8
👍1
Building ChemInformatic Agents with LangGraph
A hands-on introduction to agents and tool calling


- Build and customize AI agents that can reason, plan, and execute tasks in chemical research
- Use tool calling to connect models with cheminformatics libraries
- Explore real-world use cases like property prediction

https://colab.research.google.com/drive/1nuuVA-1RTLqUC2AyKBc1OHmfPzdhhyJG
👍1
#cmc #oprd

Quality by digital design to accelerate sustainable medicines development

If you get tired of QbD, now some people invent QbDD.
Jokes aside - good review of what was already done and how QbD can evolve in digital era.

https://doi.org/10.1016/j.ijpharm.2025.125625
👍1
#rnd
oligowiki is a curated, queryable database focused on therapeutic oligonucleotides and the chemistries that define them

https://www.oligowizard.com/wiki/
👍1
#oprd

There is always room to read about crystallisation development!
This paper presented the general idea of using rapid process modeling as a parallel instrument to the widely applied DoE-based design and scale-up.
Kind of overkill, but interesting to read for understanding how process could be described.

https://pubs.acs.org/doi/10.1021/acs.oprd.4c00199
1👍1